CO-DIAGNOSTICS, INC. AMENDED AND RESTATED EQUITY DISTRIBUTION AGREEMENTEquity Distribution Agreement • April 28th, 2025 • Co-Diagnostics, Inc. • Surgical & medical instruments & apparatus • New York
Co-Diagnostics, Inc., a company organized under the laws of Utah (the “Company”), and Piper Sandler & Co. are parties to that certain Equity Distribution Agreement dated March 16, 2023 (the “Original Agreement”). The Company, Piper Sandler & Co. and Clear Street LLC desire to amend and restate the Original Agreement in its entirely as set forth in this Amended and Restated Equity Distribution Agreement (this “Agreement”) in order to add Clear Street LLC as a sales agent under the Agreement. As further set forth in this Agreement, the Company proposes to issue and sell from time to time through Piper Sandler & Co. and Clear Street LLC (together, the “Agents” and each individually, an “Agent”), as sales agents, the Company’s common stock, par value $0.001 per share (the “Common Stock”) (such shares of Common Stock to be sold pursuant to this Agreement, the “Shares”) on terms set forth herein. Notwithstanding anything to the contrary contained herein, the parties hereto agree that complia
NEKTAR THERAPEUTICS EQUITY DISTRIBUTION AGREEMENTEquity Distribution Agreement • March 28th, 2025 • Nektar Therapeutics • Pharmaceutical preparations • New York
As further set forth in this agreement (this “Agreement”), Nektar Therapeutics, a company organized under the laws of Delaware (the “Company”), proposes to issue and sell from time to time through Piper Sandler & Co. and BTIG, LLC (collectively the “Agents” and each individually an “Agent”), as sales agents, the Company’s common stock, par value $0.0001 per share (the “Common Stock”) (such shares of Common Stock to be sold pursuant to this Agreement, the “Shares”) on terms set forth herein. Notwithstanding anything to the contrary contained herein, the parties hereto agree that compliance with the limitation set forth in Section 2 of this Agreement on the number of Shares issued and sold under this Agreement shall be the sole responsibility of the Company, and the Agents shall have no obligation in connection with such compliance.
MIROMATRIX MEDICAL INC. EQUITY DISTRIBUTION AGREEMENTEquity Distribution Agreement • July 1st, 2022 • Miromatrix Medical Inc. • Biological products, (no disgnostic substances) • New York
As further set forth in this agreement (this “Agreement”), Miromatrix Medical Inc., a company organized under the laws of Delaware (the “Company”), proposes to issue and sell from time to time through Piper Sandler & Co. (the “Agent”), as sales agent, the Company’s common stock, par value $0.00001 per share (the “Common Stock”) (such shares of Common Stock to be sold pursuant to this Agreement, the “Shares”) on terms set forth herein. Notwithstanding anything to the contrary contained herein, the parties hereto agree that compliance with the limitation set forth in Section 2 of this Agreement on the number of shares of Shares issued and sold under this Agreement shall be the sole responsibility of the Company, and the Agent shall have no obligation in connection with such compliance.
EQUITY DISTRIBUTION AGREEMENTEquity Distribution Agreement • September 4th, 2020 • Aravive, Inc. • Pharmaceutical preparations • New York
As further set forth in this agreement (this “Agreement”), Aravive, Inc., a Delaware corporation (the “Company”), proposes to issue and sell from time to time through Piper Sandler & Co. and Cantor Fitzgerald & Co. (each an “Agent”, and together, the “Agents”), as sales agents, the Company’s shares of common stock, par value $0.0001 per share (the “Common Stock”) (such Common Stock to be sold pursuant to this Agreement, the “Shares”), on terms set forth herein. Notwithstanding anything to the contrary contained herein, the parties hereto agree that compliance with the limitation set forth in Section 2 of this Agreement on the number of Shares issued and sold under this Agreement shall be the sole responsibility of the Company, and the Agents shall have no obligation in connection with such compliance.
APTOSE BIOSCIENCES INC. EQUITY DISTRIBUTION AGREEMENTEquity Distribution Agreement • May 5th, 2020 • Aptose Biosciences Inc. • Biological products, (no disgnostic substances) • New York
As further set forth in this agreement (this “Agreement”), Aptose Biosciences Inc., a company incorporated under the Canada Business Corporations Act (the “Company”), proposes to issue and sell from time to time through Piper Sandler & Co. and Canaccord Genuity LLC (each an “Agent”, and together, the “Agents”), as sales agents, the Company’s common shares, no par value per share (the “Common Shares”) (such Common Shares to be sold pursuant to this Agreement, the “Shares”) on terms set forth herein. Notwithstanding anything to the contrary contained herein, the parties hereto agree that compliance with the limitation set forth in Section 2 of this Agreement on the number of Shares issued and sold under this Agreement shall be the sole responsibility of the Company, and the Agents shall have no obligation in connection with such compliance.
GEMPHIRE THERAPEUTICS INC. EQUITY DISTRIBUTION AGREEMENTEquity Distribution Agreement • September 1st, 2017 • Gemphire Therapeutics Inc. • Pharmaceutical preparations • New York
As further set forth in this agreement (this “Agreement”), Gemphire Therapeutics Inc., a company organized under the laws of Delaware (the “Company”), proposes to issue and sell from time to time through Piper Jaffray & Co. (the “Agent”), as sales agent, the Company’s common stock, par value $0.001 per share (the “Common Stock”) (such shares of Common Stock to be sold pursuant to this Agreement, the “Shares”) on terms set forth herein. Notwithstanding anything to the contrary contained herein, the parties hereto agree that compliance with the limitation set forth in Section 2 of this Agreement on the number of Shares issued and sold under this Agreement shall be the sole responsibility of the Company, and the Agent shall have no obligation in connection with such compliance.